BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34380976)

  • 1. Immune Checkpoint Inhibitor-associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies.
    Tran AN; Wang M; Hundt M; Chugh R; Ohm J; Grimshaw A; Ciarleglio M; Hung KW; Proctor DD; Price CC; Laine L; Al-Bawardy B
    J Immunother; 2021 Oct; 44(8):325-334. PubMed ID: 34380976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk of diarrhea and colitis in patients with lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Bishay K; Tandon P; Bourassa-Blanchette S; Laurie SA; McCurdy JD
    Curr Oncol; 2020 Oct; 27(5):e486-e494. PubMed ID: 33173388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review.
    Nakane T; Mitsuyama K; Yamauchi R; Kakuma T; Torimura T
    Kurume Med J; 2023 Jul; 68(2):43-52. PubMed ID: 37100606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint Inhibitor-Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis.
    Nielsen DL; Juhl CB; Chen IM; Kellermann L; Nielsen OH
    Cancer Treat Rev; 2022 Sep; 109():102440. PubMed ID: 35917654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study.
    Sleiman J; Wei W; Shah R; Faisal MS; Philpott J; Funchain P
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34158318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course.
    Haryal A; Townsend MJ; Baskaran V; Srivoleti P; Giobbie-Hurder A; Sack JS; Isidro RA; LeBoeuf NR; Buchbinder EI; Hodi FS; Grover S
    Cancer; 2023 Feb; 129(3):367-375. PubMed ID: 36377339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis.
    Abu-Sbeih H; Herrera LN; Tang T; Altan M; Chaftari AP; Okhuysen PC; Jenq RR; Wang Y
    J Immunother Cancer; 2019 Sep; 7(1):242. PubMed ID: 31488205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer.
    Dolladille C; Ederhy S; Sassier M; Cautela J; Thuny F; Cohen AA; Fedrizzi S; Chrétien B; Da-Silva A; Plane AF; Legallois D; Milliez PU; Lelong-Boulouard V; Alexandre J
    JAMA Oncol; 2020 Jun; 6(6):865-871. PubMed ID: 32297899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesalamine and cholestyramine for immune checkpoint inhibitor-mediated diarrhea and colitis.
    Hollander B; Khurana S; Jacob JS; Altan M; Wang J; Zhao D; Varatharajalu K; Alasadi M; Thomas AS; Wang Y
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3637-3648. PubMed ID: 35972690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment and outcomes of immune checkpoint inhibitors-associated colitis/diarrhea: A systematic review and meta-analysis.
    Ding M; Zhang X; Wang J; Gao F; Zheng X; Yuan J; Qi X
    Dig Liver Dis; 2023 Dec; 55(12):1621-1631. PubMed ID: 36894390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis: A Clinical Review.
    Gong Z; Wang Y
    JCO Oncol Pract; 2020 Aug; 16(8):453-461. PubMed ID: 32584703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse Events Associated with Immune Checkpoint Inhibitors: Overview of Systematic Reviews.
    Kanji S; Morin S; Agtarap K; Purkayastha D; Thabet P; Bosse D; Wang X; Lunny C; Hutton B
    Drugs; 2022 May; 82(7):793-809. PubMed ID: 35416592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-checkpoint inhibitors induced diarrhea and colitis: a review of incidence, pathogenesis and management.
    Abu-Sbeih H; Ali FS; Wang Y
    Curr Opin Gastroenterol; 2020 Jan; 36(1):25-32. PubMed ID: 31609734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to PD-1 and PD-L1 inhibitors.
    Thomas AR; Liu C; Tong YT; Tan D; Altan M; Siddiqui BA; Shatila M; Khan A; Thomas AS; Wang Y
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5429-5436. PubMed ID: 36451045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitor-induced diarrhea: Clinicopathological study of 11 patients.
    Yanai S; Nakamura S; Kawasaki K; Toya Y; Akasaka R; Oizumi T; Ishida K; Sugai T; Matsumoto T
    Dig Endosc; 2020 May; 32(4):616-620. PubMed ID: 31595568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.
    Yu Y; Zhou Y; Zhang X; Tan K; Zheng J; Li J; Cui H
    Front Oncol; 2022; 12():934093. PubMed ID: 35912183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review.
    Asdourian MS; Shah N; Jacoby TV; Reynolds KL; Chen ST
    JAMA Dermatol; 2022 Aug; 158(8):933-941. PubMed ID: 35612829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis.
    Tandon P; Bourassa-Blanchette S; Bishay K; Parlow S; Laurie SA; McCurdy JD
    J Immunother; 2018 Apr; 41(3):101-108. PubMed ID: 29401166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
    Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
    Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.